How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review.

A large number of clinical measures of psoriasis are used in clinical trials and daily practice. These measures lack uniformity and validation. However, valid outcome and severity measures for psoriasis are a prerequisite for fully informative clinical research and evidence-based medicine. The purpose of this study was to identify all clinical measures of psoriasis severity and outcome in use and to evaluate the quality of these measures using clinimetric criteria; we identified 53 separate clinical measures, which were regrouped into 11 measures for quality analysis. No measure could be scored on all items used in the clinimetric analysis. The Lattice System Physician's Global Assessment and Physician's Global Assessment were most highly noted. We conclude that none of the psoriasis measures is adequately validated. The Psoriasis Area and Severity Index is the most commonly used clinical measure in research, but it has substantial limitations such as low response distribution, no consensus on interpretability, and low responsiveness in mild disease. Nevertheless, because of its widespread use the Psoriasis Area and Severity Index permits some degree of comparison of results among clinical trials. Overall, no best instrument was identified, and different situations may call for different measures.

[1]  A. Kimball,et al.  A critical assessment of composite and coprimary endpoints: a complex problem. , 2008, Journal of the American Academy of Dermatology.

[2]  R. Chalmers,et al.  The Salford Psoriasis Index: an holistic measure of psoriasis severity , 2000, The British journal of dermatology.

[3]  Nhs Trust.  A study examining inter-and intrarater reliability of three scales for measuring severity of psoriasis:Psoriasis Area and Severity Index,Physician's Global Assessment and Lattice System Physician's Global Assessment , 2006 .

[4]  S. Feldman,et al.  A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. , 2004, Journal of the American Academy of Dermatology.

[5]  A. Fleischer,et al.  The Self‐Administered Psoriasis Area and Severity Index provides an objective measure of psoriasis severity , 2005, The British journal of dermatology.

[6]  S. Weisman,et al.  Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis , 2003, The Journal of dermatological treatment.

[7]  C. Main,et al.  Physical and psychologic measures are necessary to assess overall psoriasis severity. , 2001, Journal of the American Academy of Dermatology.

[8]  R. Myllylä,et al.  Assessment of skin erythema by eye, laser Doppler flowmeter, spectroradiometer, two-channel erythema meter and Minolta chroma meter , 2004, Archives of Dermatological Research.

[9]  A. Gottlieb,et al.  The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. , 2003, Journal of drugs in dermatology : JDD.

[10]  C. Lawrence,et al.  Measurement of involved surface area in patients with psoriasis , 1991, The British journal of dermatology.

[11]  C. Oh,et al.  Objective assessment of involved surface area in patients with psoriasis , 2003, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[12]  S. Tiling-Grosse,et al.  Assessment of area of involvement in skin disease: a study using schematic figure outlines , 1993, The British journal of dermatology.

[13]  A. Fleischer,et al.  Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. , 1996, The Journal of investigative dermatology.

[14]  S. Feldman,et al.  The SAPASI Is Valid and Responsive to Psoriasis Disease Severity Changes in a Multi‐Center Clinical Trial , 1999, The Journal of dermatology.

[15]  A. Finlay,et al.  The rule of hand: 4 hand areas = 2 FTU = 1 g. , 1992, Archives of dermatology.

[16]  T. Agner,et al.  Colorimetric quantification of erythema—a comparison of two colorimeters (Lange Micro Color and Minolta Chroma Meter CR‐200) with a clinical scoring scheme and laser‐Doppler flowmetry , 1990, Clinical and experimental dermatology.

[17]  Griffiths,et al.  Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality , 1999, The British journal of dermatology.

[18]  F. Sera,et al.  Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. , 2004, The Journal of investigative dermatology.

[19]  H. Williams,et al.  Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. , 2003, The Journal of investigative dermatology.

[20]  S. Feldman,et al.  Psoriasis assessment tools in clinical trials , 2005, Annals of the rheumatic diseases.

[21]  A. Stanimirović,et al.  Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead‐Sea , 2000, International journal of dermatology.

[22]  A Y Finlay,et al.  Assessment of disease progress in psoriasis. , 1989, Archives of dermatology.

[23]  H. Wulf,et al.  The applicability of clinical scoring systems: SCORAD and PASI in psoriasis and atopic dermatitis. , 1997, Acta Dermato-Venereologica.

[24]  S. Feldman.  A quantitative definition of severe psoriasis for use in clinical trials , 2004, The Journal of dermatological treatment.

[25]  M. Lebwohl,et al.  The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. , 2001, Archives of dermatology.

[26]  F. Sera,et al.  Performance of the self-administered psoriasis area and severity index in evaluating clinical and sociodemographic subgroups of patients with psoriasis. , 2003, Archives of dermatology.

[27]  Steven R Feldman,et al.  A Simplified Psoriasis Area Severity Index (SPASI) for rating psoriasis severity in clinic patients. , 2004, Dermatology online journal.

[28]  Marko Kreft,et al.  Computer-aided measurement of psoriatic lesion area in a multicenter clinical trial--comparison to physician's estimations. , 2006, Journal of dermatological science.

[29]  A. Lassus,et al.  Reproducibility of Clinical Trials of Topical Glucocorticosteroids , 1983, International journal of dermatology.

[30]  R. Weller,et al.  A comparison of subjective and objective measures of reduction of psoriasis with the use of ultrasound, reflectance colorimetry, computerized video image analysis, and nitric oxide production. , 1997, Journal of the American Academy of Dermatology.

[31]  G. Kanthraj,et al.  Comparison of computer-aided design and rule of nines methods in the evaluation of the extent of body involvement in cutaneous lesions. , 1997, Archives of dermatology.

[32]  D. Ford,et al.  Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach. , 2007, General hospital psychiatry.

[33]  M. Bigby,et al.  Understanding and evaluating clinical trials. , 1996, Journal of the American Academy of Dermatology.

[34]  A. Finlay,et al.  The ‘handprint’ approximates to 1% of the total body surface area whereas the ‘palm minus the fingers’ does not , 2007, The British journal of dermatology.

[35]  J. Röning,et al.  Comparison of actual psoriasis surface area and the psoriasis area and severity index by the human eye and machine vision methods in following the treatment of psoriasis. , 1998, Acta dermato-venereologica.

[36]  Jochen Schmitt,et al.  The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis , 2005, Dermatology.

[37]  D M Reboussin,et al.  Psoriasis causes as much disability as other major medical diseases. , 1999, Journal of the American Academy of Dermatology.

[38]  C. Chams‐Davatchi,et al.  Prednisolone dosage in pemphigus vulgaris. , 2005, Journal of the American Academy of Dermatology.

[39]  H. Williams,et al.  What are the best outcome measurements for atopic eczema? A systematic review. , 2007, The Journal of allergy and clinical immunology.

[40]  U. Pettersson,et al.  Oral treatment of pustulosis palmo-plantaris with a new retinoid, Ro 10-9359. , 1979, Dermatologica.

[41]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.

[42]  R. Langley,et al.  Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. , 2004, Journal of the American Academy of Dermatology.

[43]  Assessment of severity score in patients with psoriasis , 1993, The British journal of dermatology.

[44]  J. Röning,et al.  Application of machine vision to assess involved surface in patients with psoriasis , 1997, The British journal of dermatology.

[45]  A. Fleischer,et al.  Patient measurement of psoriasis disease severity with a structured instrument. , 1994, The Journal of investigative dermatology.

[46]  K. Katz.  Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal. , 2005, Journal of the American Academy of Dermatology.

[47]  Jan Busschbach,et al.  Critical review of generic and dermatology-specific health-related quality of life instruments. , 2007, The Journal of investigative dermatology.

[48]  S. Feldman,et al.  The self-administered psoriasis area and severity index is valid and reliable. , 1996, The Journal of investigative dermatology.

[49]  C. Terwee,et al.  Quality criteria were proposed for measurement properties of health status questionnaires. , 2007, Journal of clinical epidemiology.

[50]  P.C.M. Kerkhof,et al.  On the limitations of the psoriasis area and severity index (PASI) , 1992 .

[51]  C C Jacobson,et al.  Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased , 2004, The British journal of dermatology.